<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00737880</url>
  </required_header>
  <id_info>
    <org_study_id>CL-KSM-III/6/00</org_study_id>
    <nct_id>NCT00737880</nct_id>
  </id_info>
  <brief_title>Histidine-Tryptophane-Ketoglutarate (HTK) vs University of Wisconsin (UW) Perfusion in Clinical Pancreas Transplantation</brief_title>
  <official_title>A Prospective Randomized Multicenter Trial Comparing Histidine-Tryptophane-Ketoglutarate (HTK) Versus University of Wisconsin (UW) Perfusion Solution in Clinical Pancreas Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Rostock</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. F. Köhler Chemie GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University Innsbruck</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Graft preservation in clinical pancreas transplantation is based on hypothermia achieved by
      topic cooling and cold in situ flushing using special perfusion solutions designed to
      attenuate the effects of ischemia/reperfusion and prolong cold ischemia tolerance.

      For pancreas transplantation, University of Wisconsin (UW) solution is the most commonly used
      perfusate. However, over the last years, Histidine-Tryptophan-Ketoglutarate (HTK) solution
      has been increasingly used for abdominal organ procurement. Retrospective reports published
      so far have demonstrated the safety of both perfusion solutions.

      However, to date, no prospective study comparing both perfusion solutions has been published.
      Aim of this study was to prospectively evaluate early pancreas graft function in clinical
      pancreas transplantation after organ perfusion with HTK vs. UW solution.

      The study hypothesis is that HTK is not inferior to UW for organ perfusion during procurement
      in clinical pancreas transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2001</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">January 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pancreas graft survival</measure>
    <time_frame>6 months after transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum amylase</measure>
    <time_frame>6 months after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum lipase</measure>
    <time_frame>6 months after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide</measure>
    <time_frame>6 months after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>6 months after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exogenous insulin requirement</measure>
    <time_frame>6 months after transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Pancreas Transplantation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In situ organ perfusion using HTK solution during pancreas procurement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In situ perfusion using UW solution during pancreas procurement</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Organ perfusion during pancreas procurement</intervention_name>
    <description>Usage of UW or HTK perfusion solution during in situ abdominal organ perfusion in multi-organ procurement</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  brain dead, heart beating organ donor

          -  donor age 10 - 50 years

          -  donor body mass index &lt; 30kg/m2

          -  pancreas cold ischemia time &lt; 20 hours

          -  written informed consent of the pancreas recipient

        Exclusion Criteria:

          -  missing written consent

          -  pancreas retransplantation

          -  recipient participation in another study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alfred Königsrainer, Prof., M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Transplantat Surgery, Medical University Innsbruck</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center of Operative Medicine / Department of Visceral, Transplant and Thoracic Surgery / Medical University Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <state>Tyrol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of General, Hepato-Biliary and Transplantation Surgery</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of General, Visceral and Transplantation Surgery, Charite Campus Virchow Klinikum, Humboldt University Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of General, Vascular, Thoracic and Transplantation Surgery, University of Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2008</study_first_submitted>
  <study_first_submitted_qc>August 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2008</study_first_posted>
  <last_update_submitted>August 19, 2008</last_update_submitted>
  <last_update_submitted_qc>August 19, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2008</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Alfred Königsrainer</name_title>
    <organization>Transplantation Surgery / Medical University Innsbruck</organization>
  </responsible_party>
  <keyword>Pancreas Clinical, Donor</keyword>
  <keyword>Pancreas Clinical, Preservation Solutions</keyword>
  <keyword>Organ Preservation and Procurement, Surgery</keyword>
  <keyword>Organ Procurement, Ischemia reperfusion Injury</keyword>
  <keyword>Organ Preservation and Procurement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Pancreatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

